BR122012018280B8 - composição farmacêutica compreendendo hormônio luteinizante humano e sacarose - Google Patents

composição farmacêutica compreendendo hormônio luteinizante humano e sacarose

Info

Publication number
BR122012018280B8
BR122012018280B8 BR122012018280A BR122012018280A BR122012018280B8 BR 122012018280 B8 BR122012018280 B8 BR 122012018280B8 BR 122012018280 A BR122012018280 A BR 122012018280A BR 122012018280 A BR122012018280 A BR 122012018280A BR 122012018280 B8 BR122012018280 B8 BR 122012018280B8
Authority
BR
Brazil
Prior art keywords
luteinizing hormone
pharmaceutical composition
human luteinizing
sucrose
reversed
Prior art date
Application number
BR122012018280A
Other languages
English (en)
Portuguese (pt)
Other versions
BR122012018280B1 (pt
Inventor
Paradise Gianfranco
Scaglia Laura
Rossi Mara
Original Assignee
Laboratoires Serono S A
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono S A, Merck Serono Sa filed Critical Laboratoires Serono S A
Publication of BR122012018280B1 publication Critical patent/BR122012018280B1/pt
Publication of BR122012018280B8 publication Critical patent/BR122012018280B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/36Extraction; Separation; Purification by a combination of two or more processes of different types
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Semiconductor Lasers (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
BR122012018280A 2000-02-22 2001-01-22 composição farmacêutica compreendendo hormônio luteinizante humano e sacarose BR122012018280B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00103692.0 2000-02-22
EP00103692 2000-02-22
PCT/EP2001/000666 WO2001062774A2 (en) 2000-02-22 2001-01-22 Purified lh
BRPI0108553 2001-01-22

Publications (2)

Publication Number Publication Date
BR122012018280B1 BR122012018280B1 (pt) 2018-01-09
BR122012018280B8 true BR122012018280B8 (pt) 2021-05-25

Family

ID=8167926

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122012018280A BR122012018280B8 (pt) 2000-02-22 2001-01-22 composição farmacêutica compreendendo hormônio luteinizante humano e sacarose
BRPI0108553A BRPI0108553B8 (pt) 2000-02-22 2001-01-22 processo para a purificação de hormônio luteinizante (lh) recombinante humano

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0108553A BRPI0108553B8 (pt) 2000-02-22 2001-01-22 processo para a purificação de hormônio luteinizante (lh) recombinante humano

Country Status (30)

Country Link
US (2) US7053054B2 (enExample)
EP (2) EP1777231A3 (enExample)
JP (1) JP4959898B2 (enExample)
KR (1) KR100808149B1 (enExample)
CN (1) CN100480258C (enExample)
AT (1) ATE356138T1 (enExample)
AU (1) AU780377B2 (enExample)
BG (1) BG65761B1 (enExample)
BR (2) BR122012018280B8 (enExample)
CA (1) CA2399100C (enExample)
CY (1) CY1108056T1 (enExample)
CZ (1) CZ303274B6 (enExample)
DE (1) DE60127100T2 (enExample)
DK (1) DK1261622T3 (enExample)
EA (1) EA004385B1 (enExample)
EE (1) EE04932B1 (enExample)
ES (1) ES2278722T3 (enExample)
HR (1) HRP20020651B1 (enExample)
HU (1) HU227007B1 (enExample)
IL (2) IL151309A0 (enExample)
MX (1) MXPA02007867A (enExample)
NO (1) NO328693B1 (enExample)
PL (1) PL207728B1 (enExample)
PT (1) PT1261622E (enExample)
RS (1) RS50416B (enExample)
SI (1) SI1261622T1 (enExample)
SK (1) SK287041B6 (enExample)
UA (2) UA92145C2 (enExample)
WO (1) WO2001062774A2 (enExample)
ZA (1) ZA200206108B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL207728B1 (pl) * 2000-02-22 2011-01-31 Serono Lab Sposób oczyszczania LH z próbki, zastosowanie rekombinowanego hLH oraz kompozycja farmaceutyczna
DE10235168A1 (de) * 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
NZ542549A (en) * 2003-03-04 2008-11-28 Aspenbio Pharma Inc Methods and kits for maintaining pregnancy, treating follicular cysts, and synchronizing ovulation using single-chain luteinizing hormone
CN1283792C (zh) * 2003-11-14 2006-11-08 余伟明 生物大分子组分相分离法
AU2004309040B2 (en) * 2003-12-22 2010-12-16 Ares Trading S.A. Method for purifying FSH
US20060148699A1 (en) * 2004-10-04 2006-07-06 Avi Tovi Counterion exchange process for peptides
BRPI0517973B8 (pt) * 2004-11-09 2021-05-25 Ares Trading Sa métodos para purificar o fsh recombinante
SI1917276T1 (en) 2005-08-26 2018-05-31 Ares Trading S.A. PROCEDURE FOR PREPARATION OF GLYCOSYLATED INTERFERONE BETA
AU2006323925B2 (en) * 2005-12-09 2012-08-02 Ares Trading S.A. Method for purifying FSH or a FSH mutant
US20100249381A1 (en) * 2007-10-22 2010-09-30 David Delvaille Method for Purifying FC-Fusion Proteins
AU2008314689A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying an Fc-containing protein
CN101928342B (zh) * 2009-06-18 2013-05-08 上海天伟生物制药有限公司 一种高纯度绝经期促性腺素及其制备方法和用途
CN106999546A (zh) * 2014-05-01 2017-08-01 弗吉尼亚技术知识资产公司 角蛋白纳米材料及其制备方法
CN104569441B (zh) * 2015-01-19 2016-02-03 成都大熊猫繁育研究基地 大熊猫尿液促黄体素的酶联检测方法及其应用
CA3140267A1 (en) 2019-05-16 2020-11-19 Ceva Sante Animale Compositions and methods for increasing reproduction performance in non-human mammals using recombinant luteinizing hormone

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002757A1 (en) * 1988-09-02 1990-03-22 Integrated Genetics, Inc. Heteropolymeric protein
EP0461200B1 (en) 1989-02-21 1997-01-22 Washington University Modified forms of reproductive hormones
US5087615A (en) * 1989-03-17 1992-02-11 Applied Research Systems Ars Holding N.V. Novel method of ovulation induction in humans
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
IT1287138B1 (it) * 1996-11-07 1998-08-04 Ibsa Inst Biochimique Sa Procedimento per la separazione e purificazione di fsh e lh
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
CN1302010C (zh) * 1997-06-25 2007-02-28 应用研究系统Ars股份公司 二硫键交联的糖蛋白激素类似物及其制备和应用
PL207728B1 (pl) * 2000-02-22 2011-01-31 Serono Lab Sposób oczyszczania LH z próbki, zastosowanie rekombinowanego hLH oraz kompozycja farmaceutyczna

Also Published As

Publication number Publication date
US20030186893A1 (en) 2003-10-02
CN100480258C (zh) 2009-04-22
AU3543601A (en) 2001-09-03
WO2001062774A3 (en) 2002-03-14
RS50416B (sr) 2009-12-31
CA2399100A1 (en) 2001-08-30
EE04932B1 (et) 2007-12-17
PL362891A1 (en) 2004-11-02
PL207728B1 (pl) 2011-01-31
JP2003532636A (ja) 2003-11-05
MXPA02007867A (es) 2003-02-10
BG107001A (bg) 2003-04-30
US7053054B2 (en) 2006-05-30
HRP20020651B1 (en) 2011-01-31
BRPI0108553B8 (pt) 2021-05-25
ES2278722T3 (es) 2007-08-16
EP1777231A3 (en) 2007-11-07
ZA200206108B (en) 2003-07-31
HU227007B1 (en) 2010-04-28
WO2001062774A2 (en) 2001-08-30
CY1108056T1 (el) 2013-09-04
NO20023963L (no) 2002-08-20
DK1261622T3 (da) 2007-05-29
EP1261622B1 (en) 2007-03-07
IL151309A0 (en) 2003-04-10
AU780377B2 (en) 2005-03-17
NO328693B1 (no) 2010-04-26
IL151309A (en) 2010-11-30
CA2399100C (en) 2011-11-08
PT1261622E (pt) 2007-04-30
SI1261622T1 (sl) 2007-06-30
BRPI0108553B1 (pt) 2016-06-14
US20060079460A1 (en) 2006-04-13
EA004385B1 (ru) 2004-04-29
HUP0301814A3 (en) 2004-10-28
DE60127100T2 (de) 2007-06-28
HUP0301814A2 (hu) 2003-08-28
UA78676C2 (en) 2007-04-25
ATE356138T1 (de) 2007-03-15
EE200200464A (et) 2003-12-15
CZ20022856A3 (cs) 2003-01-15
SK287041B6 (sk) 2009-10-07
BR0108553A (pt) 2003-12-23
EP1777231A2 (en) 2007-04-25
DE60127100D1 (de) 2007-04-19
NO20023963D0 (no) 2002-08-20
HRP20020651A2 (en) 2004-12-31
CZ303274B6 (cs) 2012-07-11
SK12052002A3 (sk) 2002-12-03
BR122012018280B1 (pt) 2018-01-09
EA200200893A1 (ru) 2003-02-27
EP1261622A2 (en) 2002-12-04
KR100808149B1 (ko) 2008-02-29
KR20030001358A (ko) 2003-01-06
CN1404486A (zh) 2003-03-19
JP4959898B2 (ja) 2012-06-27
BG65761B1 (bg) 2009-10-30
HK1052014A1 (zh) 2003-08-29
YU60302A (sh) 2005-09-19
UA92145C2 (en) 2010-10-11

Similar Documents

Publication Publication Date Title
BR122012018280B8 (pt) composição farmacêutica compreendendo hormônio luteinizante humano e sacarose
CY1108460T1 (el) Μεθοδος για τον καθαρισμο ανασυνδυασμενης hcg (ανθρωπινης χοριονικης γοναδοτροπινης) που εχει ειδικη βιοδραστικοτητα
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
EP0695171A1 (en) GONADOTROPINE CONTAINING FREEZER DRIED DROPS
RU2005118752A (ru) Позиционные изомеры пэгилированного интерферона l-2а (конъюгата пэг-ifn-l-2а)
BR0312521A (pt) Métodos para a separação e a purificação de fibrinogênio e de pelo menos uma outra proteìna e para a co-purificação de fibrinogênio e de fator xiii, uso de cromatografia de afinidade com ìon de metal imobilizado, fibrinogênio, kit farmacêutico, e, formulações farmacêutica e de fibrinogênio liofilizado
BR0306878A (pt) Peptìdeo não-agonista do receptor de fator de liberação de corticotropina 2, ácido nucleico e anticorpo isolados, composição farmacêutica e kit compreendendo o referido peptìdeo e uso do referido peptìdeo e ácido nucleico na fabricação de um medicamento
ITPD920073A1 (it) Metodo per la preparazione e purificazione di miscele di fosfolipidi prive di contaminanti da virus non convenzionali
DK0417003T3 (da) Anvendelse af antiprogestomimetiske forbindelser til fremme af ovulation
AR014884A1 (es) Uso de un conjugado de angiotensina inmunogenico y composicion farmaceutica
BR0315265A (pt) Composto de feromÈnio dauer farmacologicamente ativo para controlar o envelhecimento e tensão e método para isolar e caracterizar o mesmo
AR003926A1 (es) Variante de adnasa humana i, ácido nucleico que la codifica, uso de dicha variante para preparar medicamentos útiles en el tratamiento de una enfermedad o afección pulmonar y una composición farmacéutica que contiene dicha variante.
CL2004000978A1 (es) Compuestos derivados de pirazolopirimidinas sustituidos de formula definida, inhibidores de pde; procedimiento para su preparacion; composicion farmaceutica que los contiene y sus usos para preparar medicamentos que sirven para tratar trastornos de l
ITMI20000262A0 (it) Uso del tiamfenicolo per la preparazione di composizioni farmaceutiche utili per il trattamento di infezioni da staphylococci vancomicino-in
MX9401370A (es) Terapia antiviral.
AR028928A1 (es) Analogos del peptido intestinal vasoactivo
ECSP034554A (es) 3,4-DIHIDRO-PIRIMIDO(1,2-a) PIRIMIDINA Y 3,4-DIHIDRO-PIRAZINO (1,2-a) PIRAMIDINA SUSTITUIDAS

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MERCK SERONO S.A. (CH)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O ARTIGO 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/01/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 22/01/2021